Table 2.

VEGF, mutational, and multivariate analysis

A. VEGF expression status versus primary tumor location and kit exon 11 or non–exon 11 mutation status versus VEGF expression status
VEGF Status
Total (%)
Negative-weakly positiveStrongly positive
Primary tumor site
    Stomach (%)21 (91)2 (9)23 (44)
    Small bowel (%)14 (82)3 (18)17 (32)
    Colon (%)5 (100)0 (0)5 (9)
    Other (%)*4 (50)4 (50)8 (15)
    Total (%)44 (83)9 (17)53
kit genotype
    Exon 11 (%)28 (85)5 (15)33 (62)
    Non–exon 11 (%)16 (80)4 (20)20 (38)
    Total (%)44 (83)9 (17)53
B. Multivariate analysis by log-logistic model for PFS and Cox proportional model for OS are displayed

Variable
Coefficient
SD
P
Log-logistic model for PFSExon 11 versus non–exon 110.860.30.004
Weak VEGF versus no VEGF−0.090.310.76
Strong VEGF versus no VEGF−0.960.420.02
Cox proportional model for OSExon 11 versus non–exon 11−0.410.450.36
Weak VEGF versus No VEGF0.120.050.81
Strong VEGF versus No VEGF1.490.60.03
Log (mitosis + 1)1.550.760.04
Log (mitosis + 1)2−0.40.210.06
  • * Other = mesenteric, esophageal, liver, or peritoneal lesion.

  • Significant prognostic factors affecting PFS and OS are shown.